<DOC>
	<DOCNO>NCT02170207</DOCNO>
	<brief_summary>The purpose survey evaluate safety ( , frequency adverse event ) efficacy ( , hemostatic effect , rate rebleeding confirmation hemostasis ) administration lansoprazole intravenous 30 milligram ( mg ) ( Takepron Intravenous 30 mg ) large number participant acute stress ulcer acute gastric mucosal lesion daily medical practice .</brief_summary>
	<brief_title>Takepron Intravenous 30 mg Specified Drug-use Survey Acute Stress Ulcer Acute Gastric Mucosal Lesions</brief_title>
	<detailed_description>This survey design evaluate safety ( , frequency adverse event ) efficacy ( i.e. , hemostatic effect , rate rebleeding confirmation hemostasis ) administration lansoprazole intravenous 30 mg ( Takepron Intravenous 30 mg ) large number participant acute stress ulcer acute gastric mucosal lesion daily medical practice . For adult , 30 mg lansoprazole typically mixed physiological saline ( JP ) 5 percent ( % ) glucose solution injection ( JP ) administer twice daily drip infusion dissolve 20 mL physiological saline ( JP ) 5 % glucose solution injection ( JP ) administer twice daily direct slow intravenous injection .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<criteria>Participants follow disease oral administration feasible : Acute stress ulcer , acute gastric mucosal lesion ( accompany bleeding ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Pharmacological therapy</keyword>
</DOC>